Healthcare Providers and Services
Company Overview of NewBridge Pharmaceuticals FZ-LLC
NewBridge Pharmaceuticals FZ-LLC, a specialty therapeutics company, focuses on pharmaceuticals, biologics, and medical diagnostics. It specializes in in-licensing, acquiring, registering, and commercializing to address the unmet medical needs of diseases with regional prevalence in the Middle East, Africa, Turkey, and Caspian regions. Its products include oncology and supportive care products, such as Abstral, a sublingual tablet for the treatment of pain in cancer patients; Clasteon, a bisphosphonate for the management of osteolysis resulting from bone metastases of malignant tumors, as well as for the management of hypercalcemia and bone pain of malignancy; Sancuso, a skin patch for the pr...
P.O. Box 500618
Business Central Tower A.
Office # 2405
Dubai Internet City
United Arab Emirates
Founded in 2007
Key Executives for NewBridge Pharmaceuticals FZ-LLC
Co-Founder and Vice President of Corporate Strategy & Business Development
Personal Assistant to President & Chief Executive Officer
Compensation as of Fiscal Year 2013.
NewBridge Pharmaceuticals FZ-LLC Key Developments
Eisai Plans to Market Halaven in Select Countries Within the Middle East Region Through New Partnership Between Eisai EMEA and NewBridge Pharmaceuticals
Nov 19 13
Eisai is planning to market Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. The product is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease.
Eisai EMEA Announces Partnership with NewBridge Pharmaceuticals to Market Breast Cancer Treatment Halaven(R) (Eribulin) Across the Middle East
Nov 18 13
Eisai announced that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments.
Newbridge Pharmaceuticals and Verinata Health, Inc. to Commercialize the Verifi(R) Prenatal Test
Feb 14 13
NewBridge Pharmaceuticals FZ-LLC announced that the company has established an exclusive agreement with Verinata Health, Inc. to expand access to Verinata's verifi(R) test, the most comprehensive non-invasive prenatal test (NIPT) currently available for high-risk pregnancies. The verifi(R) prenatal test is performed in Verinata's CLIA-certified, California laboratory using a single maternal blood draw as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies (an abnormal number of chromosomes). Under the terms of the collaboration agreement, NewBridge will serve as the exclusive Verinata Health commercial partner for the sales and marketing of the verifi(R) test in the countries of the Middle East, Turkey, Africa and Caspian regions. Financial terms of the agreement were not disclosed. Traditionally, doctors have used invasive tests such as amniocentesis or chorionic villus sampling (CVS) to determine the chromosomal status of a fetus during a woman's pregnancy. Using a routine blood sample from the mother, the verifi(R) test detects Down syndrome (trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13), as well as the most common fetal sex chromosome aneuploidies including Turner syndrome (Monosomy X), Triple X (XXX), Klinefelter syndrome (XXY) and Jacobs syndrome (XYY).
Similar Private Companies By Industry
Recent Private Companies Transactions
May 20, 2013